Skip to content

Evaluating theophylline efficacy in ADCY5-related disease Dyskinesia - a prospective study

Evaluating theophylline efficacy in ADCY5-related disease Dyskinesia - a prospective study - ETAD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00034720
Enrollment
15
Registered
2024-07-25
Start date
2024-07-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G24.8

Interventions

Group 1: Patient group with ADCY5-related dyskinesia who was prescribed theophylline by their attending physician Using a questionnaire (uploaded as an attachment), anonymous data on symptoms, the hi

Sponsors

Medizinische Fakultät Leipzig
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Consent of the patients or guardians to the analysis of the anonymized data

Exclusion criteria

Exclusion criteria: no proof of ADCY5 mutation

Design outcomes

Primary

MeasureTime frame
Observation of therapeutic effects of theophylline on the symptoms of ADCY5 dyskinesia WHAT: Influence of theophylline on symptoms. WHEN: at a time chosen by the patient or family within the recruitment window. There is therefore no specification of a specific theophylline dose or a specific clinical condition. HOW: using a questionnaire: here a list of typical ADCY5-associated symptoms is offered and explained. The effects of theophylline are asked about using a Likert scale

Secondary

MeasureTime frame
Tolerance of theophylline The questionnaire contains questions about adverse drug reactions (ADRs), which are answered by the patient/family. These ADRs are related to the indicated dose of theophylline.

Countries

Australia, Germany, United States

Contacts

Public ContactAndreas Merkenschlager

Medizinische Fakultät Leipzig

Andreas.Merkenschlager@medizin.uni-leipzig.de+493419726322

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026